ACLY与慢性肾脏病:一项孟德尔随机化分析
研究利用eQTLGen中31684名参与者的血液样本构建ACLY表达遗传工具,在两样本孟德尔随机化分析中评估遗传预测的ACLY表达对CKD、eGFR和ACR的影响,数据来自CKDGen、UK Biobank和FinnGen共66396例CKD病例和958517例对照。结果显示ACLY表达评分降低34%与CKD风险降低9%相关(OR=0.91,95%CI:0.85-0.98,P=0.008),但与eGFR或ACR无关联。
要点
- ACLY表达评分降低34%与CKD风险降低9%相关(OR=0.91,95%CI:0.85-0.98,P=0.008)。
- ACLY表达评分降低34%与LDL胆固醇降低0.04 mmol/l相关(P=3.4×10⁻⁴)。
- 遗传预测的ACLY表达与eGFR或ACR无关联。
核心结论
- 孟德尔随机化分析显示,遗传预测的ACLY表达降低与CKD风险降低相关,但对eGFR或ACR无影响。
- 作者认为有必要进一步评估ACLY在肾脏疾病中的作用。
研究设计与样本
- 两样本孟德尔随机化分析,利用eQTLGen中31684名参与者血液样本构建ACLY表达遗传工具。
- 遗传工具包含13个变异,解释全血ACLY基因表达变异的1.5%。
- 结局数据来自CKDGen、UK Biobank和FinnGen,共66396例CKD病例和958517例对照。
主要发现
- ACLY在所有细胞类型包括全血中组成性表达。
- ACLY表达评分降低34%与LDL胆固醇降低0.04 mmol/l相关(P=3.4×10⁻⁴)。
- ACLY表达评分降低34%与CKD(3、4、5期、透析或eGFR<60 ml/min per 1.73 m²)风险降低9%相关(OR=0.91,95%CI:0.85-0.98,P=0.008)。
- 遗传预测的ACLY表达与eGFR或ACR均无关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adenosine triphosphate-citrate lyase (ACLY) inhibition is a therapeutic strategy under investigation for atherosclerotic cardiovascular disease, nonalcoholic steatohepatitis, and metabolic syndrome. Mouse models suggest that ACLY inhibition could reduce inflammation and kidney fibrosis. Genetic analysis of ACLY in chronic kidney disease (CKD) has not been performed. METHODS: We constructed a genetic instrument by selecting variants associated with ACLY expression in the expression quantitative trait loci genetics consortium (eQTLGen) from blood samples from 31,684 participants. In a 2-sample Mendelian randomization analysis, we evaluated the effect of genetically predicted ACLY expression on the risk of CKD, estimated glomerular filtration rate (eGFR), and albumin-to-creatinine ratio (ACR) using the CKD Genetics (CKDGen) consortium, UK Biobank, and the Finnish Genetics (FinnGen) consortium totaling 66,396 CKD cases and 958,517 controls. RESULTS: ACLY is constitutively expressed in all cell types including in whole blood. The genetic instrument included 13 variants and explained 1.5% of the variation in whole blood ACLY gene expression. A 34% reduction in ACLY expression score was associated with a 0.04 mmol/l reduced low-density lipoprotein (LDL) cholesterol (P = 3.4 × 10-4) and a 9% reduced risk of CKD (stages 3, 4, 5, dialysis, or eGFR < 60 ml/min per 1.73 m2) (odds ratio [OR] = 0.91, 95% CI: 0.85-0.98, P = 0.008), but no association was observed with either eGFR or ACR. CONCLUSION: Mendelian randomization analyses revealed that genetically reduced ACLY expression was associated with reduced risk of CKD but had no effect on either eGFR or ACR. Further evaluation of ACLY in kidney disease is warranted.
引用
- Mohammadi-Shemirani P, Chong M, Perrot N, et al. ACLY and CKD: A Mendelian Randomization Analysis. Kidney Int Rep. 2022. PMID: 35812273. doi:10.1016/j.ekir.2022.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。